Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 9/2021

01-09-2021 | Sexually Transmitted Infection | Original Paper

Characterizing Biomedical HIV Prevention Awareness and Use Among Black Transgender Women in the United States

Authors: Cristian J. Chandler, Stephanie L. Creasy, Brian J. Adams, Lisa A. Eaton, Leigh A. Bukowski, James E. Egan, M. Reuel Friedman, Ronald D. Stall, Darren L. Whitfield

Published in: AIDS and Behavior | Issue 9/2021

Login to get access

Abstract

Black transgender women (BTW) in the United States experience disproportionate rates of HIV despite biomedical prevention interventions such as pre-exposure prophylaxis (PrEP) and non-occupational post-exposure prophylaxis (nPEP). Using a sample of 490 BTW collected from 2014 to 2017, bivariate, multivariable, and multinomial analyses were conducted to determine factors associated with awareness and use of PrEP and nPEP. BTW living with HIV were more aware of PrEP than HIV-negative BTW. Structural, demographic, and trans-specific factors (e.g., experiences of homelessness, violence, and current hormone use) related to HIV risk were associated with PrEP and nPEP awareness. PrEP use was associated with behavioral HIV risks (e.g., STI diagnosis, having an HIV-positive partner, and needle-sharing) and may demonstrate risk recognition among BTW. Knowing someone using PrEP was significantly positively associated with PrEP use. Development of guidelines for PrEP and nPEP use for BTW should leverage the strengths of guidelines for other populations, while also acknowledging the unique risks for this population.
Literature
1.
James SE, Herman J, Rankin S, Keisling M, Mottet L, Anafi Ma. The report of the. US transgender survey: executive summary. Washington, DC: National Center for Transgender Equality; 2015. p. 2017.
2.
3.
Poteat T, Scheim A, Xavier J, Reisner S, Baral S. Global epidemiology of HIV infection and related syndemics affecting transgender people. J Acquir Immune Defic Syndr. 1999;72(Suppl 3):S210.
4.
Reback CJ, Fletcher JB. HIV prevalence, substance use, and sexual risk behaviors among transgender women recruited through outreach. AIDS Behav. 2014;18(7):1359–67.PubMedPubMedCentralCrossRef
5.
Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13:214–22.PubMedCrossRef
6.
Herbst JH, Jacobs ED, Finlayson TJ, McKleroy VS, Neumann MS, Crepaz N, et al. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. AIDS Behav. 2008;12(1):1–17.PubMedCrossRef
7.
Bukowski LA, Chandler CJ, Creasy SL, Matthews DD, Friedman MR, Stall RD. Characterizing the HIV care continuum and identifying barriers and facilitators to HIV diagnosis and viral suppression among black transgender women in the United States. J Acquir Immune Defic Syndr. 1999;79(4):413.CrossRef
8.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.PubMedPubMedCentralCrossRef
9.
Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.PubMedCrossRef
10.
Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.PubMedCrossRef
11.
McAllister J, Read P, McNulty A, Tong W, Ingersoll A, Carr A. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. HIV Med. 2014;15(1):13–22.PubMedCrossRef
12.
Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, et al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV. 2015;2(12):e512–9.PubMedPubMedCentralCrossRef
13.
Escudero DJ, Kerr T, Operario D, Socías ME, Sued O, Marshall BD. Inclusion of trans women in pre-exposure prophylaxis trials: a review. AIDS Care. 2015;27(5):637–41.PubMedCrossRef
14.
Grohskopf LA, Chillag KL, Gvetadze R, Liu AY, Thompson M, Mayer KH, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013;64(1):79–86.PubMedCrossRef
15.
De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016;119:1–7.PubMedCrossRef
16.
Centers for Disease Control and Prevention. Preexpoure prophylaxis for the prevention of HIV infection in the United State: 2017 update: clinical practice guideline 2018. Washington, DC: Centers for Disease Control and Prevention; 2017.
17.
Jones J, Hoenigl M, Siegler A, Sullivan P, Little S, Rosenberg E. Assessing the performance of three HIV incidence risk scores in a cohort of black and white MSM in the South. Sex Transm Dis. 2017;44(5):297.PubMedPubMedCentralCrossRef
18.
Lancki N, Almirol E, Alon L, McNulty M, Schneider JA. PrEP guidelines have low sensitivity for identifying seroconverters in a sample of Young Black men who have sex with men in Chicago. AIDS. 2018;32(3):383.PubMedCrossRef
19.
Siembida EJ, Eaton LA, Maksut JL, Driffin DD, Baldwin R. A comparison of HIV-related risk factors between Black transgender women and Black men who have sex with men. Transgend Health. 2016;1(1):172–80.PubMedPubMedCentralCrossRef
20.
Patel VV, Masyukova M, Sutton D, Horvath KJ. Social media use and HIV-related risk behaviors in young black and Latino gay and bi men and transgender individuals in New York City: implications for online interventions. J Urban Health. 2016;93(2):388–99.PubMedPubMedCentralCrossRef
21.
22.
Kuhns LM, Reisner SL, Mimiaga MJ, Gayles T, Shelendich M, Garofalo R. Correlates of PrEP indication in a multi-site cohort of young HIV-uninfected transgender women. AIDS Behav. 2016;20(7):1470–7.PubMedPubMedCentralCrossRef
23.
Denson DJ, Padgett PM, Pitts N, Paz-Bailey G, Bingham T, Carlos J-A, et al. Health care use and HIV-related behaviors of black and Latina transgender women in 3 US metropolitan areas: Results from the transgender HIV behavioral survey. J Acquir Immune Defic Syndr. 1999;75(Suppl 3):S268.
24.
Crosby RA, Salazar LF, Hill B, Mena L. A comparison of HIV-risk behaviors between young black cisgender men who have sex with men and young black transgender women who have sex with men. Int J STD AIDS. 2018;29(7):665–72.PubMedCrossRef
25.
Wilson EC, Santos G-M, Raymond HF. Sexual mixing and the risk environment of sexually active transgender women: data from a respondent-driven sampling study of HIV risk among transwomen in San Francisco, 2010. BMC Infect Dis. 2014;14(1):430.PubMedPubMedCentralCrossRef
26.
Gamarel KE, Reisner SL, Darbes LA, Hoff CC, Chakravarty D, Nemoto T, et al. Dyadic dynamics of HIV risk among transgender women and their primary male sexual partners: the role of sexual agreement types and motivations. AIDS Care. 2016;28(1):104–11.PubMedCrossRef
27.
Santos GM, Rapues J, Wilson EC, Macias O, Packer T, Colfax G, et al. Alcohol and substance use among transgender women in San Francisco: prevalence and association with human immunodeficiency virus infection. Drug Alcohol Rev. 2014;33(3):287–95.PubMedCrossRef
28.
Smith DK, Pals SL, Herbst JH, Shinde S, Carey JW. Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2012;60(4):421–7.PubMedCrossRef
29.
Reisner SL, Bailey Z, Sevelius J. Racial/ethnic disparities in history of incarceration, experiences of victimization, and associated health indicators among transgender women in the US. Women Health. 2014;54(8):750–67.PubMedPubMedCentralCrossRef
30.
Arayasirikul S, Wilson EC, Raymond HF. Examining the effects of transphobic discrimination and race on HIV risk among transwomen in San Francisco. AIDS Behav. 2017;21(9):2628–33.PubMedPubMedCentralCrossRef
31.
Poteat T, Wirtz AL, Radix A, Borquez A, Silva-Santisteban A, Deutsch MB, et al. HIV risk and preventive interventions in transgender women sex workers. Lancet. 2015;385(9964):274–86.PubMedCrossRef
32.
Sugano E, Nemoto T, Operario D. The impact of exposure to transphobia on HIV risk behavior in a sample of transgendered women of color in San Francisco. AIDS Behav. 2006;10(2):217.PubMedCrossRef
33.
Mimiaga MJ, Hughto JM, Biello KB, Santostefano CM, Kuhns LM, Reisner SL, et al. Longitudinal analysis of syndemic psychosocial problems predicting HIV risk behavior among a multicity prospective cohort of sexually active young transgender women in the United States. J Acquir Immune Defic Syndr. 2019;81(2):184–92.PubMedPubMedCentralCrossRef
34.
Holder CL, Perez-Gilbe HR, Fajardo FJ, Garcia S, Cyrus E. Disparities of HIV risk and PrEP use among transgender women of color in South Florida. J Natl Med Assoc. 2019;111(6):625–32.PubMed
35.
Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDs. 2013;27(4):248–54.PubMedPubMedCentralCrossRef
36.
Sevelius JM, Deutsch MB, Grant R. The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. J Int AIDS Soc. 2016;19:21105.PubMedPubMedCentralCrossRef
37.
Garnett M, Hirsch-Moverman Y, Franks J, Hayes-Larson E, El-Sadr WM, Mannheimer S. Limited awareness of pre-exposure prophylaxis among black men who have sex with men and transgender women in New York city. AIDS Care. 2018;30(1):9–17.PubMedCrossRef
38.
Foster R, McAllister J, Read TR, Pierce AB, Richardson R, McNulty A, et al. Single-tablet emtricitabine-rilpivirine-tenofovir as HIV postexposure prophylaxis in men who have sex with men. Clin Infect Dis. 2015;61(8):1336–41.PubMedCrossRef
39.
Centers for Disease Control and Prevention. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV: United States, 2016. Washington, DC: Centers for Disease Control and Prevention; 2016.
40.
Wilson E, Rapues J, Jin H, Raymond HF. The use and correlates of illicit silicone or “fillers” in a population-based sample of transwomen, San Francisco, 2013. J Sex Med. 2014;11(7):1717–24.PubMedPubMedCentralCrossRef
41.
Operario D, Nemoto T. HIV in transgender communities: syndemic dynamics and a need for multicomponent interventions. J Acquir Immune Defic Syndr. 1999;55(Suppl 2):S91.
42.
Safer JD, Coleman E, Feldman J, Garofalo R, Hembree W, Radix A, et al. Barriers to health care for transgender individuals. Curr Opin Endocrinol Diabetes Obes. 2016;23(2):168.PubMedPubMedCentralCrossRef
43.
Wilson EC, Jin H, Liu A, Raymond HF. Knowledge, indications and willingness to take pre-exposure prophylaxis among transwomen in San Francisco, 2013. PLoS ONE. 2015;10(6):e0128971.PubMedPubMedCentralCrossRef
44.
Jayakumaran JS, Aaron E, Gracely J, Schriver E, Szep Z. Knowledge, attitudes, and acceptability of pre-exposure prophylaxis among individuals living with HIV in an urban HIV clinic. PLoS ONE. 2016;11(2):e0145670.PubMedPubMedCentralCrossRef
45.
Brooks RA, Cabral A, Nieto O, Fehrenbacher A, Landrian A. Experiences of pre-exposure prophylaxis stigma, social support, and information dissemination among Black and Latina transgender women who are using pre-exposure prophylaxis. Transgend Health. 2019;4(1):188–96.PubMedPubMedCentralCrossRef
46.
Dilley J, McFarl and W, Kellogg T, editors. Use of a unique testing code among anonymous testers to track repeat tests, estimate HIV incidence, and identify risk factors for HIV seroconversion [abstract MoPpD1132]. 13th International AIDS Conference, Durban, 2000.
47.
Hammer GP, Kellogg TA, McFarland WC, Wong E, Louie B, Williams I, et al. Low incidence and prevalence of hepatitis C virus infection among sexually active non-intravenous drug-using adults, San Francisco, 1997–2000. Sex Transm Dis. 2003;30(12):919–24.PubMedCrossRef
48.
49.
Matthews DD, Herrick A, Coulter RW, Friedman MR, Mills TC, Eaton LA, et al. Running backwards: consequences of current HIV incidence rates for the next generation of black MSM in the United States. AIDS Behav. 2016;20(1):7–16.PubMedPubMedCentralCrossRef
50.
Mehrotra ML, Amico KR, McMahan V, Glidden DV, Defechereux P, Guanira JV, et al. The role of social relationships in PrEP uptake and use among transgender women and men who have sex with men. AIDS Behav. 2018;22(11):3673–80.PubMedPubMedCentralCrossRef
51.
Kaeble D, Cowhig M. Correctional populations in the United States, 2016. NCJ-251211. Washington, DC: US Department of Justice; 2016.
52.
Maruschak LM, Minton TD. Correctional populations in the United States, 2017–2018. Washington, DC: US Department of Justice, Office of Justice Programs, Bureau of Justice Statistics; 2020.
53.
Reisner SL, Radix A, Deutsch MB. Integrated and gender-affirming transgender clinical care and research. J Acquir Immune Defic Syndr. 1999;72(Suppl 3):S235.
54.
Sevelius JM, Keatley J, Calma N, Arnold E. ‘I am not a man’: trans-specific barriers and facilitators to PrEP acceptability among transgender women. Global Public Health. 2016;11(7–8):1060–75.PubMedCrossRef
55.
Rael CT, Martinez M, Giguere R, Bockting W, MacCrate C, Mellman W, et al. Barriers and facilitators to oral PrEP use among transgender women in New York City. AIDS Behav. 2018;22(11):3627–36.PubMedPubMedCentralCrossRef
56.
Arnold EA, Sterrett-Hong E, Jonas A, Pollack LM. Social networks and social support among ball-attending African American men who have sex with men and transgender women are associated with HIV-related outcomes. Global Public Health. 2018;13(2):144–58.PubMedCrossRef
57.
Poteat T, German D, Flynn C. The conflation of gender and sex: gaps and opportunities in HIV data among transgender women and MSM. Global Public Health. 2016;11(7–8):835–48.PubMedPubMedCentralCrossRef
Metadata
Title
Characterizing Biomedical HIV Prevention Awareness and Use Among Black Transgender Women in the United States
Authors
Cristian J. Chandler
Stephanie L. Creasy
Brian J. Adams
Lisa A. Eaton
Leigh A. Bukowski
James E. Egan
M. Reuel Friedman
Ronald D. Stall
Darren L. Whitfield
Publication date
01-09-2021
Publisher
Springer US
Published in
AIDS and Behavior / Issue 9/2021
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-021-03189-w

Other articles of this Issue 9/2021

AIDS and Behavior 9/2021 Go to the issue

Original Paper

Differences in Access to HIV Services and Risky Sexual Behaviors Among Malawian Women at Social Venues Who Do and Do Not Engage in Sex Work

Original Paper

Male Partner Involvement and Development of HIV-exposed Infants in Rural South Africa

Original Paper

PrEP Awareness, Use, Intention to Use, and Information Source Among Geosocial Networking Application Users in Mexico in 2018–2019

Original Paper

Understanding Women’s Vaginal Douching Behaviors and Practices for Consideration in the Development of a Potential Future Vaginal Microbicide Douche for HIV Prevention: A Systematic Review of the Literature

Original Paper

Understanding the Reasons for Deferring ART Among Patients Diagnosed Under the Same-Day-ART Policy in Johannesburg, South Africa

Original Paper

South African Fathers Involvement and Their Adolescents’ Sexual Risk Behavior and Alcohol Consumption
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits